The letter arrives on a Tuesday, or maybe it's buried in a patient portal message you almost miss. Your prior authorization has been denied. The drug your doctor prescribed, the one that took months of specialist visits and genetic testing to arrive at, will not be covered.
For patients with common conditions, this is frustrating. For patients with rare diseases, where the drug in question might be the only FDA-approved therapy in existence, it can feel like a death sentence.
It isn't. The system is designed to say no first. The numbers prove it.
Why Do Insurers Deny Rare Disease Medications?
In 2022, Medicare Advantage plans denied 17% of prior authorization requests, according to a report from the HHS Office of Inspector General (OIG). That number alone is striking. What follows is worse: fewer than 1% of patients who received a denial appealed it. Among those who did, 44% had their denials overturned on internal appeal.
Read those numbers again. Nearly half of all appealed denials were reversed, yet 99% of patients never tried.
Private commercial plans show similar patterns. A 2023 KFF analysis found that marketplace insurers denied roughly 17% of in-network claims, with appeal rates hovering below 1 in 500. The pattern is the same across the board. Insurers deny at high rates, patients rarely push back, and when they do, the denial often collapses.
Rare disease patients face a compounded version of this. Orphan drugs are expensive. The average annual cost of an orphan drug in the US reached $150,854 per patient in 2023 (IQVIA Institute). Some gene therapies cost millions for a single administration. Insurers have strong financial incentives to delay and deny, and the prior authorization process gives them a mechanism to do it.
Prior Authorization Denied: What Are Your Options?
Prior authorization is a requirement that your doctor get pre-approval from the insurer before prescribing certain medications. In theory, it exists to prevent unnecessary treatments. In practice, it has become a gatekeeping tool that delays care across the board. A 2024 AMA survey found that 94% of physicians reported care delays due to prior authorization, and 80% said it sometimes led patients to abandon treatment entirely.
When a PA is denied, the insurer is required to provide a reason. The most common ones are that the drug is not on formulary, the patient hasn't tried required step therapies, the clinical documentation doesn't meet the plan's coverage criteria, or the insurer considers the treatment "experimental" or "investigational." That last category is particularly common for orphan drugs that received FDA approval under accelerated pathways.
Each of these reasons has a corresponding counter-strategy. Knowing which one you're dealing with determines your next move.
Step Therapy Laws: When "Fail First" Puts Patients at Risk
Step therapy protocols require patients to try cheaper medications before the insurer will cover the prescribed drug. For a patient with Type 2 diabetes, this might mean trying metformin before a GLP-1 agonist. Annoying, perhaps, but not dangerous. For a child with Batten disease or spinal muscular atrophy, being forced to "fail first" on an ineffective therapy can mean irreversible neurological damage during the waiting period.
32 states have enacted step therapy reform laws as of 2025. These laws vary, but most require insurers to grant exceptions when the required step therapy drug is clinically inappropriate, when the patient has already tried the drug (including under a different plan), or when the delay would cause irreversible harm. Texas, Virginia, and New York have some of the strongest protections.
How Peer-to-Peer Review Can Reverse a Drug Denial
This is the most underused tool in the appeals process. After a denial, your prescribing physician can request a peer-to-peer review, which is a phone call between your doctor and the insurer's medical director. The physician explains the clinical rationale for the drug, and the medical director makes a coverage determination on the call or shortly after.
These calls work. Approximately 80% of peer-to-peer reviews result in an approval or a partial approval, according to data from specialty pharmacy benefit managers. The reason is simple. The initial denial was made by a utilization reviewer following a checklist. The peer-to-peer puts a specialist in direct conversation with a physician who can explain why the checklist doesn't apply.
Many physicians skip peer-to-peer reviews because they're time-consuming and scheduling is difficult. Some insurance plans bury the process, making it hard to find the right phone number or department. Patients can help by asking their doctor's office directly whether a peer-to-peer has been requested. If the answer is no, push for it.
How to File an Internal Appeal for a Denied Medication
Every insurer is required by law to offer at least one level of internal appeal. Under the ACA, you have 180 days from the date of denial to file. The insurer must respond within 30 days for non-urgent requests and 72 hours for urgent ones.
This is where documentation wins or loses the case. A strong internal appeal includes the denial letter with the specific reason cited, a letter of medical necessity from the prescribing specialist, relevant clinical studies or FDA approval data supporting the drug, chart notes demonstrating the patient's disease severity, and documentation of any prior therapies attempted.
For orphan drugs specifically, include the FDA approval letter, the drug's orphan designation, and any clinical trial data showing efficacy in your specific condition. If the drug was approved under accelerated approval, include post-marketing confirmatory study data if available.
External Review: Your Right to an Independent Decision
If internal appeals fail, the ACA guarantees the right to an independent external review for all non-grandfathered health plans. This means your case goes to a third-party reviewer who has no financial relationship with the insurer. The external reviewer's decision is binding.
External review is free to the patient. The insurer pays for it. The reviewer must be a clinical expert in the relevant specialty, and they evaluate the case based on current medical evidence, not the insurer's internal coverage policies.
A Georgetown University Health Policy Institute analysis found that external reviews overturn insurance denials in approximately 39-59% of cases, depending on the state and type of denial. For rare disease drugs where the clinical evidence is strong, the success rate tends to fall on the higher end of that range.
“81.7% of prior authorization denials that were appealed through all levels were ultimately overturned.”
HHS Office of Inspector General, 2022
Retroactive Denials: When Coverage Disappears After Treatment
This one blindsides families. You've been receiving the drug for months, sometimes years. The insurer approved it. Then a letter arrives saying coverage is being retroactively denied, and you owe the full cost of treatment already received.
Retroactive denials happen for several reasons. The insurer conducts a post-payment audit and decides the original authorization was granted in error. The patient's plan changes at renewal and the new formulary excludes the drug. Or the insurer reclassifies the drug as experimental after initially covering it.
Many states have laws limiting retroactive denials, particularly when the provider obtained valid prior authorization. California, Illinois, and Connecticut have strong protections. If you receive a retroactive denial, file a complaint with your state's Department of Insurance immediately. Do not pay the balance without disputing it first.
Free Help for Insurance Denials: Advocates, Programs, and Attorneys
Patient Advocacy Organizations
NORD (National Organization for Rare Disorders) launched the Claim Your Care initiative in March 2025 specifically to help rare disease patients fight insurance denials. The program connects patients with case managers who understand orphan drug coverage and can assist with appeal documentation. Disease-specific organizations like the Cystic Fibrosis Foundation, MDA, and NAMI also maintain insurance navigation programs.
Patient Assistance Programs
Many orphan drug manufacturers offer bridge or patient assistance programs that can provide the drug at no cost while coverage or an appeal is pending, but terms vary widely and some companies offer none. Ask the manufacturer's support program directly what it offers for your drug. These are not charity. They are strategic: the manufacturer wants the patient established on the drug so the insurer eventually covers it. Use them.
State Insurance Commissioners
Filing a complaint with your state's Department of Insurance or Insurance Commissioner's office is free and surprisingly effective. Insurers track complaint ratios, and regulators investigate patterns. A single complaint might not change a policy, but it creates a record. In states with strong consumer protection laws, the commissioner's office can intervene directly in denial disputes.
Attorneys
Health insurance attorneys typically work on contingency for denial cases involving high-cost drugs. If your appeal has been denied at all levels and the dollar amount is significant (most orphan drugs qualify), an ERISA attorney or health insurance coverage lawyer may take the case. The Patient Advocate Foundation maintains a directory of attorneys who specialize in insurance denials.
Insurance Appeal Timeline: What to Do After a Denial
The day the denial letter arrives, read the specific reason. Call the insurer and request the full clinical criteria they used to make the decision. Ask for it in writing.
Within the first few days, contact your prescribing specialist. Ask them to request a peer-to-peer review. At the same time, contact the drug manufacturer's patient services line to apply for bridge supply, which is free drug while the appeal is pending.
If the peer-to-peer doesn't resolve it within two weeks, file the internal appeal. Include the letter of medical necessity, clinical evidence, and all supporting documentation. Send via certified mail or fax with confirmation.
If the internal appeal is denied around the 30 to 45 day mark, file for external review immediately. Contact NORD or a disease-specific advocacy org for help with documentation. File a complaint with your state insurance commissioner.
If the external review fails (uncommon for well-documented rare disease cases), consult with a health insurance attorney. The Patient Advocate Foundation can help identify one.
What Happens If You Don't Appeal a Drug Denial?
Insurance companies process millions of prior authorizations per year. Their denial rates are calibrated around the assumption that most patients will accept the first no. The appeals process exists because legislators recognized this dynamic and built in safeguards. Those safeguards work, but only when patients use them.
For rare disease families already exhausted by the daily realities of managing a complex condition, fighting an insurance company feels like one more impossible task. It shouldn't fall to you. Until the system changes, though, the data is clear: patients who appeal win more often than they lose.
The first denial is not the final answer. Treat it as the opening of a process, not the end of one.